Royalty Report: Drugs, Vaccine, Drug Discovery – Collection: 307944

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 17

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 17

Primary Industries

  • Drugs
  • Vaccine
  • Drug Discovery
  • Cancer
  • Respiratory
  • Disease
  • Viral Infection
  • Delivery
  • HIV / AIDs
  • Medical
  • Device
  • Diagnostic
  • cell therapy
  • Herpes
  • Therapeutic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 307944

License Grant
Under the Collobaration Agreement, Licensor will make the Ii-Key Peptide vaccine technology available to the Chinese Licensees. The Chinese parties will provide facilities and personnel for the development of the COVID-19 vaccine under Licensor technical guidance. The development will include synthesis, analysis and human trials through Phase III, if warranted, in China. The Chinese parties will have exclusive rights to use and commercialize the COVID-19 technology and products in China.
License Property
The licensed property is Ii-Key Peptide vaccine technology.  Ii-Key is a technology that activates the immune response for the treatment of cancer and infectious diseases.
Field of Use
The field of use is to develop a COVID-19 vaccine.  The COVID-19 pandemic has opened significant opportunities to resurrect infectious disease vaccine platform Ii-Key Peptide vaccine technology.  COVID-19 is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Licensee is an affiliate of the China Technology Exchange, and is enabling the development of the COVID-19 vaccine in China.

IPSCIO Record ID: 306663

License Grant
The Licensee entered into a worldwide nonexclusive License Agreement with the Licensor, the primary agency of the United States government responsible for biomedical and public health research, for the use of certain patents and tangible materials to be used in the development and commercialization of a vaccine for the SARS-CoV-2 virus.
License Property
The focus is on the development of a vaccine for the SARS-CoV-2 virus and other strains of coronavirus using patented and patent-pending technology.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 is the strain of coronavirus that causes coronavirus disease 2019 (COVID-19), the respiratory illness responsible for the COVID-19 pandemic.

Field of Use
Licensee focus is on developing novel antibiotics against infectious diseases; especially a vaccine for the SARS-CoV-2 virus and other strains of coronavirus using patented and patent-pending technology. The goal is accelerating the development of much needed new antibiotics that can work against resistant strains of bacteria and the development of biotherapeutics for oral mucositis and other diseases and conditions of the oral cavity, throat, and esophagus.

IPSCIO Record ID: 322230

License Grant
Under the terms of the worldwide licensing agreement with the Licensor, the Licensee will adapt the coronavirus test to run on its T2Dx Instrument.
License Property
T2Dx Instrument has the ability to rapidly identify COVID-19.

The COVID-19 molecular diagnostic test is designed to detect the presence of the SARS-CoV-2 virus in a nasopharyngeal swab sample.

Coronavirus disease (COVID-19) is an infectious disease caused by a coronavirus (called SARS-CoV-2), a contagious respiratory illness.

Field of Use
The field of use is for the detection of the SARS-CoV-2 virus.

SARS-CoV-2 virus is a coronavirus that causes a contagious respiratory illness.

Licensee is a diagnostics company that develops innovative and proprietary technology platforms that target treatments for early detection of a variety of diseases including COVID-19 (SARS-CoV-2 virus).

IPSCIO Record ID: 305251

License Grant
With this asset purchase agreement Buyer acquired an exclusive license with respect to Premas’ vaccine platform.
License Property
The sole asset consists of an exclusive license with respect to Premas’ vaccine platform for the development of a vaccine against COVID-19 and other coronavirus infections.

Premas vaccine platform is certain patent applications, know-how and other proprietary information related to a vaccine platform that involves genetically engineered and modified yeast, Saccharomyces cerevisiae, which along with certain proprietary expression vectors and optimized genes developed to be used with the above strain, and, has been shown to be useful in the expression of more than thirty type 1 endoplasmic reticulum associated proteins.

Field of Use
The field of use is infection and disease.  The Field of the Premas’ vaccine platform shall encompass the vaccination against, and prevention, treatment, and management, of COVID-2019 and any mutations thereof, and any other novel corona virus and any mutations thereof.  COVID-19, new Corona Virus has three major antigens or immunogens which are type 1 endoplasmic reticulum associated proteins, primarily the “S” spike protein, “E” Envelope protein and “M”, membrane protein.

IPSCIO Record ID: 298360

License Grant
This agreement is to form a joint venture entity to cooperate and use commercially reasonable efforts to exchange information and resources that will lead to the development of Licensed Products.
License Property
The Licensee has rights to VaxCelerate, a self-assembling vaccine (SAV) platform exclusively licensed by Licensee from the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital (MGH).

Licensor is is a clinical-stage biopharmaceutical company with expertise in the pre-clinical and clinical development of pharmaceutical products.

Licensed Product means products and services that are made, made for, used, imported, offered for sale or sold by Company or its Affiliates or sublicensees in the field.

Field of Use
License is  for the development of vaccine prospects for Coronavirus (COVID-19) based upon VaxCelerate, a self-assembling vaccine platform.

•VaxCelerate offers two unique elements to combat the Coronavirus – one fixed immune adjuvant and one variable immune targeting and offers several potential advantages over other compounds in combination therapy.

The vaccine focuses on both DNA and internal/external mutated proteins providing the immune system with more potential targets to attack.

Field shall mean all products and processes or uses developed hereunder, whether or not related to the Patent Rights, for the prevention, interception or treatment of COVID-19 and other related corona viruses, or otherwise.

IPSCIO Record ID: 310513

License Grant
The Foundation conducted a clinical study for the Company for two phase II clinical trials to determine if a vaccine containing AE37 plus GM-CSF or another peptide vaccine compound (GP2) plus GM-CSF improved patient outcomes. Pursuant to the Forbearance Agreement, the Company and the Foundation in exchange for the Foundations deferring the Company’s overdue payments, future payments and interest, the Company agreed, among other things to pay the Foundation certain royalties and accelerated payments.
License Property
AE37 (Ii-Key-HER2/neu peptide immunotherapeutic vaccine) is an Ii-Key-Hybrid molecule that contains the HER2/neu antigenic peptide linked to the Ii-Key to enhance immune stimulation against HER2, which is expressed in numerous cancers, including breast, prostate, and bladder cancers.

Ii-Key is a peptide derived from the major histocompatibility complex (MHC) Class II associated invariant chain (Ii) that regulates the formation, trafficking, and antigen-presenting functions of MHC class II complexes, essential for the activation of T cells in the immune response. T cells recognize antigenic epitopes when they are ‘presented’ to them by specific molecules, termed (MHC) on the surface of infected or malignant cells. This interaction activates the T cells, stimulating a multicellular cascade of actions that eliminates the diseased cell and protects against future disease recurrence.

In 2006 Phase I clinical trial was completed of AE37 in breast cancer, including a phase Ib safety and immunology study of AE37 in combination with GM-CSF in 16 breast cancer patients who had completed all first-line therapies and who were disease-free at the time of enrollment to the study (Holmes et al. Results of the first phase I clinical trial of the novel Ii-Key hybrid preventive HER-2/neu peptide (AE37) vaccine. J Clin Oncol 2008;263426-33).

The Foundation conducted the study, under the sponsorship of an institute affiliated with the United States Military until the IND #12229 was transferred to the Company, after which Foundation continued trial management on behalf of the Company.

The Foundation is a nonprofit organization dedicated to advancing medicine by administering, managing and supporting preeminent scientific programs.

Field of Use
AE37 (Ii-Key-HER2/neu peptide immunotherapeutic vaccine) is for the treatment of breast cancer.

Licensee is an oncology company focused on the modulation of the immune system to treat cancer and is developing immunotherapeutic products and vaccines based on our proprietary, patented platform technology, Ii-Key.

IPSCIO Record ID: 297935

License Grant
Licensee has exclusively licensed the Xpress CF technology for the vaccine field from Licensor, who has industrialized and scaled the platform at its GMP facility.

Under a license from Licensor, Licensee has right to use the XpressCF® and XpressCF+™ platforms to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases.

License Property
Licensor retains the right to discover and develop vaccines for treatment or prophylaxis of any disease not caused by an infectious pathogen, including cancer.

XpressCF® – integrated cell-free protein synthesis platform

XpressCF+â„¢ –  site-specific conjugation platform

Both of these platforms allow to rapidly and precisely create optimally designed, next-generation protein therapeutics candidates.

The platform represents a major advancement over conventional conjugate vaccine production methods, by enabling precise and consistent conjugation of antigens to site-specific locations on a protein carrier that do not impede T-cell help resulting in higher-potency conjugates.

Field of Use
XpressCF® and XpressCF+â„¢ technology platforms  led to the discovery of STRO-001 and STRO-002, Licensor’s first two internally-developed ADCs. STRO-001 is a CD74-targeting ADC currently being investigated in a Phase I clinical trial of patients with advanced B-cell malignancies, including multiple myeloma and non-Hodgkin lymphoma.

IPSCIO Record ID: 343584

License Grant
As part of the BNT162 program, Licensor entered a strategic alliance with Licensee to develop COVID-19 vaccine candidates in China. German Licensor granted Chinese Licensee an exclusive license under certain of our owned or in-licensed intellectual property, including our patents relating to replicons, uridine RNA and modified RNA and other mRNA technology or a vaccine to use, develop, commercialize and otherwise exploit the vaccine candidates in the Licensee Territory. In the event of any failure of the development of a vaccine, Licensor agreed to grant Licensee a right of first negotiation on a separate competent vaccine for the prophylaxis of COVID-19 in the Licensee Territory.
License Property
Intellectual Property, includes but not limited to, patents relating to replicons, uridine RNA and modified RNA and other mRNA technology or a vaccine.

BNT162 is a vaccine program to prevent COVID-19.

Field of Use
Field of use is to for prophylaxis against SARS-CoV-2 in humans.

SARS-CoV-2 is influenza in humans.

A prophylactic is a medication or a treatment designed and used to prevent a disease from occurring.

IPSCIO Record ID: 340468

License Grant
Licensor will grant to Licensee an exclusive (even as to Licensor except as necessary for Licensor to perform its obligation hereunder and under the Development Plan) , worldwide license including the right to sublicense through multiple tiers of sublicensees under the Licensed IP, to discover, develop, make, have made, use, sell, have sold, offer for sale, market, export, import and otherwise commercialize and exploit Products in the Field in the Territory.

Licensor will grant to Licensee an exclusive, worldwide license under Licensors rights in certain patents and related intellectual property, or the License, in which Licensee will receive certain rights relating to Licensor’s proprietary oral delivery technology to further develop, manufacture and commercialize oral vaccines for COVID-19 and other novel coronaviruses based on proprietary vaccine technology involving a triple antigen virus like particle, or the Product.

License Property
Product shall mean any oral vaccines for COVID-19 and other novel coronaviruses utilizing the Licensee Technology for use in the Field that is integrated with or delivered by way of the Licensed IP under this Agreement.

Licensed IP means Patent Rights, Know-How and Information related to Licensor’s proprietary PODTM oral delivery technology involving a triple antigen virus like particle, or the Product.

The oral COVID-19 vaccine being developed promoted both systemic immunity through Immunoglobulin G (IgG), the most common antibody in blood and bodily fluids that protects against viral infections, and Immunoglobulin A (IgA).

Field of Use
Field shall encompass the vaccination against, and prevention, treatment, and management, of COVID-19 and any mutations thereof, and any other novel coronavirus and any mutations thereof after the Effective Date, and any symptoms related to the foregoing

Licensee is focused on the development of novel oral COVID-19 vaccines based on Licensor’s proprietary PODTM oral delivery technology as well as novel vaccine technology that was previously assigned to Licensee.

IPSCIO Record ID: 304735

License Grant
Licensee is granted the following rights to the Patent Applications and the Licensed Products derived therefrom.  The licenses granted herein are exclusive worldwide licenses to make, have made, use, lease, sell and import Licensed Products for the legal purposes of researching, developing, manufacturing, assembling, distributing, and selling the Licensed Products.
License Property
Patent Applications specifically related to methods of treatment for Covid-19.

Licensed Products are products designed in the Field of Covid-19 Treatment (Covid-19 Licensed Products).

Issued Patents related to the patent applications
U.S. Patent 9,216,386 – Sequential extracorporeal treatment of bodily fluids
U.S. Patent 8,758,287 – Utilization of stents for the treatment of blood borne carcinomas

Intellectual Property shall mean any Confidential Information proprietary to the Disclosing Party and any trademark, service mark, trade name, invention, improvement, discovery, patent, patent application, trade secret, copyright, copyrightable work, trade dress, mask work, computer program or any other type of proprietary intellectual property to which the Disclosing party claims any rights, including any registrations or applications for registration or renewals of any of the foregoing, and all copies and tangible embodiments of the foregoing in whatever form or medium. Confidential information shall also mean any information not generally made available or known to the public and shall include, without limitation, all ideas, inventions, software, documentation, flowcharts, diagrams, improvements, discoveries, research and development, know how, formulas, compositions, manufacturing and production processes and techniques, technical data, designs, drawings, plans, specifications, and all other information or material within the definition of a “trade secret” as set forth in the Uniform Trade Secret Act, or which either party otherwise reasonably considers proprietary.

Field of Use
The field of use is for the extracorporeal treatment of a patient’s body fluid to treat Covid-19 (Field of Covid-19 Treatment).  This treatment is intended to eliminate Covid-19 antigens and potential mutations.

(COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

IPSCIO Record ID: 308733

License Grant
This collaboration is for the Development of vaccine product candidates which incorporate one or more Licensee Antigens and the Licensed Adjuvant.

For the Exclusive License, the Licensor of Sweden grants an exclusive license, with the right to grant sublicense, under the Licensed Technology to import, make, have made, use, sell, offer for sale and otherwise exploit Licensed Products in the Exclusive Field in the Territory and otherwise exploit the Licensed Know-How in connection therewith.

For the Time-Limited Exclusive License, Licensor grants an exclusive, limited in time license, with the right to grant sublicenses, under the Licensed Technology to import, make, have made, use, sell, offer for sale and otherwise exploit Licensed Products in the Time-Limited Exclusive Field in the Territory and otherwise exploit the Licensed Know-How in connection therewith.

For the Non-Exclusive License, Licensor grants a nonexclusive  license, with the right to grant sublicenses, under the Licensed Technology to import, make, have made, use, sell, offer for sale and otherwise exploit Licensed Products in the Non-Exclusive Field in the Territory and otherwise exploit the Licensed Know-How in connection therewith; provided, however, that with respect to the Joint Technology.

License Property
Licensor owns or otherwise controls certain intellectual property relating to the Licensed Adjuvant.

Licensee Antigen means any antigen (a) owned or otherwise Controlled by Licensee and (b) believed to trigger an immune response causing the production of antibodies and/or cytokine or T-cell responses in humans as a defense against or treatment for a Disease Field.

Licensed Adjuvant means an adjuvant Controlled by Licensor which incorporates or is developed from Matrix-A, Matrix-C and/or Matrix-M technology.

Licensed Product means any vaccine product containing both the Licensed Adjuvant and one or more Licensee Antigens; provided, however a Licensed Product may include a combination vaccine product for two or more Disease Fields but not a combination vaccine product for a Disease Field and a field that is not a Disease Field.

Matrix-A means a component of the Matrix M adjuvant that is produced by mixing together HPLC-purified fraction A from Quillaja saponin bark, cholesterol and phosphatidyl choline to form Iscom particles.

Matrix-C means a component of the Matrix M adjuvant that is produced by mixing together HPLC-purified fraction C from Quillaja saponin bark, cholesterol and phosphatidyl choline to form Iscom particles.

Matrix-M means a suspension of Matrix A and Matrix C particles that are combined in varying ratios of Matrix A to Matrix C.

Field of Use
The Field means the Exclusive Field, the Time-Limited Exclusive Field, and the NonExclusive Field.   The Exclusive Disease Fields shall be herpes simplex virus (HSV) and Chlamydia.  The Selection of Time-Limited Exclusive Field is until twelve (12) months after the Effective Date, and Licensee shall have the right, at any time, to appoint up to three (3) Time-Limited Exclusive Disease Fields.  The Selection of Non-Exclusive Fields is until twenty-four (24) months after the Effective Date, and Licensee shall have the right, at any time, to appoint up to five (5) NonExclusive Disease Fields.

The agreement grants Licensee license to two patent families, to import, make, have made, use, sell, offer for sale and otherwise exploit licensed vaccine products containing an adjuvant which incorporates or is developed from Matrix-A, Matrix-C and/or Matrix-M technology, in the fields of HSV and chlamydia, and the time-limited exclusive fields of Neisseria gonorrhoeae, cytomegalovirus, or CMV, and Mycobacterium tuberculosis.

Licensee is a clinical stage biotechnology company that discovers and develops novel vaccines to address infectious diseases for which no vaccine or vaccines with limited effectiveness exist today, using a proprietary discovery platform, ATLAS, to rapidly design vaccines that act through T cell (or cellular) immune responses, in contrast to approved vaccines, which are designed to act primarily through B cell (or antibody) immune responses. Licensee is also developing a second T cell vaccine candidate, GEN-004 for pneumococcus, a leading cause of infectious disease mortality worldwide.

IPSCIO Record ID: 328343

License Grant
Licensor grants to Licensee an exclusive license under Licensor know-how and Licensor Patent Rights to develop, make, have made, use and sell Licensed Products in the territory with the right to grant sublicenses to affiliates of Licensee and those persons or entities through whom Licensee,  in the normal course of its business collaborates in the manufacture and sale of its products; provided, however, that nothing in this Agreement shall prohibit Licensor from utilizing the Licensor know-how and/or Licensor Patent Rights, exclusive of Licensee Know-how, to develop, make, have made, use and sell, either by itself or with one or more third  parties, products for the treatment of human infectious diseases.
License Property
Technology pertaining to the intramuscular delivery of vaccines for the prevention of human infectious disease that consist of DNA and/or RNA gene sequences derived from the genome of the infectious agent which would prevent clinical disease from an infection.

AIDS Vaccine means a vaccine which would prevent an infection by Human Immunodeficiency Virus (HIV-1) and/or clinical diseases caused by infection with HIV-1 in humans.

Influenza Vaccine means a vaccine which would prevent an infection and/or significant clinical diseases caused by any influenza virus in humans.

Licensed Product means a bulk or finished AIDS Vaccine or Influenza Vaccine, or other vaccine for the prevention of human infectious disease if licensed hereunder, which utilizes the Technology or technology which is developed by Licensor during and as a result of the Research Collaboration Program; provided, however, that if any such vaccine is also capable of being used for treatment of the same human infectious disease, then such therapeutic use of such vaccine shall also be considered a Licensed Product for purposes of the license being granted by Licensor to Licensee under this Agreement.

Field of Use
Field of Use is for the prevention of human infectious disease.

IPSCIO Record ID: 217567

License Grant
Licensor granted Chinese Licensee an exclusive license to use Licensor’s patents, know-how, data and other intellectual property relating to Licensor’s AE37 peptide to develop and sell products for the prevention and treatment of prostate cancer in China (including Taiwan, Hong Kong and Macau).
License Property
Peptide name AE37 (li-Key/HER2/neu776-790)

AE37 is an immunotherapeutic vaccine for prostate cancer.  AE37, an Ii-Key-Hybrid molecule that contains the HER2/neu antigenic peptide linked to the Ii-Key to enhance immune stimulation against HER2, which is expressed in numerous cancers, including breast, prostate, and bladder cancers.

Trade name AE37

Field of Use
AE37 peptide is to develop and sell products for the prevention and treatment of prostate cancer.

IPSCIO Record ID: 257492

License Grant
Pursuant to the Agreement, Licensee obtained an exclusive license under Licensor patent rights and know-how to develop, make, have made, use and sell Licensed Products in the Territory.

With this amendment the parties wish to amend the Agreement to provide for the reversion of rights to Licensor under the Licensor patent rights and know-how for Influenza vaccine, HPV vaccine and HSV vaccine.

As of the Amendment Effective Date, the license granted to Licensee, and the rights and obligations of Licensee and Licensor arising therefrom, shall no longer apply to Influenza vaccine, HPV Vaccine and HSV Vaccine, and these vaccines shall no longer be deemed to be Licensed Products under the Agreement.

Hereby amended Licensor grants to Licensee an exclusive license, even as to Licensor, under Licensor know-how and patent rights to develop, make, have made, use and sell Licensed products in the Territory with the right to grant sub licenses to Affiliates of Licensee and those persons or entities through whom Licensee, in the normal course of its business collaborates in the manufacture and sale of its products; provided however, that nothing in this Agreement shall prohibit Licensor from utilizing the Licensor know-how and/or patent rights, exclusive of Licensee know-how, to develop, make, have made, use and sell, either by itself or with one or more third parties, products for the treatment of infectious diseases provided, further, notwithstanding the preceding proviso, that Licensor shall not have any right to develop, make, have made, use, or sell, either by itself or with one or more third parties, Treatment Vaccines.

Licensor grants an option to obtain a license under theLicensor patent rights and know-how to make, have made, use, sell, offer to sell and import Cancer Vaccines in the Territory for up to three (3) Cancer targets. Such Cancer target license shall be exclusive, even as to Licensor, for each Cancer Target so licensed, and shall be sublicenseable by Licensee pursuant to the terms applicable to Licensed Products.

License Property
This amendment includes Amended Definitions Relating to Cancer targets, and, Licensed Product means a bulk or finished AIDS Vaccine, or other vaccine for the prevention of human infectious disease if licensed hereunder, which utilizes the Technology or technology which is developed by Licensor during and as a result of the research collaboration program; and upon the exercise of an Option for a Cancer vaccine, such bulk or finished Cancer vaccine for the prevention of Cancer Indications, provided, however, that if any vaccine is also capable of being used for treatment of the same human infectious disease or Cancer indication, then such therapeutic use of such vaccine shall also be considered a Licensed Product for purposes of the license being granted by Licensor to Licensee under this Agreement; and Treatment vaccines.

Treatment vaccines means a bulk or finished vaccine.

Field of Use
The field of use is for the treatment of Human Immunodeficiency Virus (HIV-1) and/or diseases caused by infection with HIV-1 in humans;  Hepatitis Virus (HBV) and or diseases caused by infection with HBV in humans; and Cancer vaccines for the treatment, but not prevention or prevention and treatment, of Cancer Indications.

IPSCIO Record ID: 305790

License Grant
Under this license, Licensee received an exclusive, worldwide, royalty-bearing, sublicenseable license under Licensor’s patents and know-how relating to cell-free expression of proteins to (i) research, develop, use, sell, offer for sale, export, import and otherwise exploit specified vaccine compositions, such rights being sublicensable, for the treatment or prophylaxis of infectious diseases, excluding cancer vaccines, and (ii) manufacture, or have manufactured by an approved contract manufacturing organization, such vaccine compositions from extracts supplied by Licensor pursuant to the Licensor Supply Agreement.  Licensee is obligated to use commercially reasonable efforts to develop, obtain regulatory approval for and commercialize the vaccine compositions.
License Property
The vaccine compositions used the Licensors proprietary cell-free protein expression technology, known as XpressCF which utilizes extracts derived from strains of E. Coli.

Licensor is a clinical stage, publicly-traded drug discovery, development and manufacturing company using precise protein engineering and rational design (enabled by Licensors proprietary XpressCF platform technology) to advance next-generation oncology therapeutics.

The primary invention underpinning the XpressCF platform was the creation of engineered E.coli-derived proprietary extracts containing fully functional oxidative phosphorylation machinery in inverted membrane vesicles and orthogonal tRNA capable of catalyzing nnAA incorporation. This innovation enables the Extract to regenerate high energy phosphates required for protein translation and nnAA incorporation, reducing production cost and permitting the use of industrial sized reaction vessels and longer manufacturing run times than previously thought possible. The XpressCF system routinely produces g/L of complex proteins in 8-10 hours and scales linearly from bench to large-scale GMP production. The protein of interest is produced at high yield and the absence of cellular debris combine to simplify downstream purification, further enhancing production efficiency.

Field of Use
The XpressCF platform is used in the field of vaccines to address infectious diseases in both human and animal use.

XpressCFâ„¢, an industrialized cell-free protein synthesis platform, for the vaccine field allowing (1) site-specific conjugation; (2) production of complex antigens in more optimal conformation; and (3) speed, flexibility and scalability of the discovery engine.

The XpressCF platform overcomes these significant limitations by separating the precise cellular machinery required for transcription, translation, and energy production into an E.coli-derived mixture, or Extract capable of continuous oxidative phosphorylation.

Licensee is a next-generation vaccine company whose cell-free protein synthesis platform enables the design and production of optimized protein carriers and antigens, the critical building blocks of vaccines.

IPSCIO Record ID: 368651

License Grant
Licensor grants a worldwide, exclusive license to Licensor Patent Rights and Know-How to make, have made, use, import, offer to sell, and sell Product using Licensed Compound supplied by Licensor, or supplied by a third party, for use in the Field.

This agreement includes a non-exclusive grant back from Licensee to Licensor.

License Property
Licensor, through its Drug Delivery Systems Division, has expertise and technology, with know-how and patents owned by Licensor, relating to toll-like receptor TLR 7 and/or 8 immune response modifier (IRM) compounds, formulations, conjugation, delivery, and manufacturing including proprietary IRM compounds such as resiquimod and others, that are useful as vaccine adjuvants.

The Compound is designated by Licensor as Resiquimod (R-848), S36212, 1-(4-aminobutoxy) -2-butyl-lH-imidazo (4,5-cl quinolin-4-amine and conjugates thereof.

Product shall mean any combination of a Licensee Antigen Presenting Cell or APC Targeting Technology vaccine with a Licensed Compound to be utilized as a Vaccine Adjuvant.

Vaccine Adjuvant shall mean a Licensed Compound which is used to induce, augment, fine-tune, enhance, or desensitize an antigen-specific immune response to an antigen contained in a vaccine or generated by a DNA vaccine for the therapeutic treatment of an existing disease or prophylactic use as protection against future disease, including desensitization to allergens. The antigen and the vaccine adjuvant may be admixed, delivered simultaneously, conjugated, or delivered separately, provided however, that the separate administration of the antigen and vaccine adjuvant is limited to the topical, dermal or mucosal or intradermal routes of administration and must be administered within 48 hours at substantially the same site and labeled as such by the applicable regulatory authority.

TLR compounds, also called TLR7 and TLR8 agonists, are small organically synthesized molecules that offer flexibility in formulating and route of delivery, and ease in manufacturing, unlike most other TLR agonists, which are much larger and not as easy to manufacture.

Field of Use
Licensor’s patented TLR immune response modifier compounds, which may be useful as vaccine adjuvants, will be used by Licensee to develop new vaccine products.  This license agreement provides a great opportunity to combine synergistic technologies designed to treat various cancers and infectious diseases.

The Field shall mean human prophylactic or therapeutic vaccination against any and all cancer disease states and selected infectious diseases.

This agreement focus is Cancer and the Infectious Diseases
– human immunodeficiency virus (HIV);
– human papillomavirus (HPV); and,
– hepatitis B virus (HBV).

IPSCIO Record ID: 319599

License Grant
Licensor, one of the nation’s leading research universities in topics such as health sciences, hereby grants to Licensee a limited, transferable (solely to Patriot Scientific or any purchaser of Licensee), exclusive license (referred to as Evaluation License) to evaluate the Materials for use in the Field of Use and to practice any method, process or procedure during the Evaluation Period solely for purposes of the Evaluation. The Evaluation License will terminate upon the expiration or termination of this Agreement, unless extended by mutual agreement. No other evaluation license will be granted in the Field of Use for the Evaluation Period.

Licensor hereby grants to Licensee the exclusive option to enter into a license agreement from Licensor for the commercial development, use, and sale of the Technology, products based on the Technology, patents, trade secrets, know-how, and other information related to the Technology;

License Property
Technology shall mean Materials or any intellectual property developed by Licensee from Materials including without limitation, all or any of the inventions and developments related thereto or arising out of any compositions, data, strains, patent applications, processes, techniques, contained therein and any physical embodiments thereof.

Materials shall mean the materials and/or intellectual property listed
– Licensor IDF Number 2013-2417 entitled “Non-Covalent Loading of Plant Picornavirus Particles” with US Patent Application US2015/0376578 A1 and EP Patent Application 14754692.3
– Licensor IDF Number 2015-2767 entitled “Cancer Immunotherapy using Virus Particles with US Patent Application US2018/0133304 A1 and associated foreign patent applications in Japan, China, Canada, Australia, and EP, US non-published patent application with patent serial number 16/612,214, and PCT Patent application with publication number WO 2018/208828 A1
– Licensor IDF Number 2017-3151 entitled “Melt Processed Viral Nanoparticle Constructs” with US Patent Application US2019/0350871 A1 and EP Patent Application 17868454.4

Patents shall mean any patent that issues or has issued to Licensor or patent application covering or consisting of the Technology and based on intellectual property in existence as of the Effective Date and any related patent or patent application that is a continuation, continuation-in-part, divisional, or reissue in the United States of America or any other country.

Field of Use
The technology is a novel platform technology using virus-like nanoparticles to treat and prevent cancer and infectious diseases in humans and for veterinary use.

The technology also has direct application as part of a vaccine platform, which has generated promising data in both cancer and infectious diseases, including COVID-19.
The researchers have collectively demonstrated that plant-derived, engineered VLP-based nanotechnologies stimulate a potent anti-tumor immune response in mouse models of metastatic melanoma, ovarian cancer, colon cancer, brain cancer and breast cancer, including companion dogs with metastatic melanoma. This data supports the potential to translate preclinical studies into veterinary applications, such as the treatment of cancer in companion animals, which has high relevance to human melanoma.
This immuno-oncology approach provides a personalized treatment approach by relieving the patient’s tumor-mediated immunosuppression and potentiating anti-tumor immunity against antigens expressed by their own tumor.

The vaccine platform is a natural extension of the immune-stimulating properties of the VLP, combined with directing the response to pre-defined targets. Instead of being a personal vaccine, the modular approach of linking disease specific targets to the VLP allows the potential to rapidly develop countermeasures for pandemics such as COVID-19.

Field of Use shall mean all therapeutic, diagnostic, vaccine and preventive uses of Technology for both veterinary and human applications. Final field of use, including specific indications, which may be narrower than the Field of Use, will be defined in any commercial use license. Said commercial use license will necessarily incorporate developmental, regulatory, and commercial distribution/sales milestones for each product that incorporates any Technology in the Field of Use. For clarification purposes, Technology and Materials shall not be used in or on humans during the Evaluation Period unless Licensee consults with Licensor regarding appropriate, and possibly expanded, indemnification and insurance requirements and receives Licensor’s written authorization to do so. Such authorization will be in Licensor’s sole discretion.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.